NOV 17, 202656 MINS READ
Croscarmellose Sodium is synthesized through internal cross-linking of sodium carboxymethylcellulose via pH reduction and thermal treatment, yielding a fibrous, water-insoluble polymer with a particle size distribution where 90% of particles are ≤44.5 μm 2. The cross-linked architecture is fundamental to its purity profile: incomplete cross-linking or residual unreacted carboxymethyl groups can lead to gum formation upon hydration, compromising both purity and functionality 2. High-purity Croscarmellose Sodium maintains particle integrity in aqueous environments, avoiding paste formation that would indicate impurity or degradation 2.
Key purity parameters include:
The fibrous morphology of high-purity Croscarmellose Sodium, observable via scanning electron microscopy (SEM), is a qualitative purity indicator: uniform fibril structure without amorphous aggregates suggests minimal degradation or contamination 2.
Rigorous purity evaluation employs a multi-technique approach to quantify chemical composition, physical properties, and functional performance:
Pharmaceutical-grade Croscarmellose Sodium must comply with compendial monographs (USP/NF, Ph. Eur., JP) and regulatory guidelines (FDA, EMA, ICH):
Leading manufacturers (e.g., FMC Corporation's Ac-Di-Sol®, Asahi Kasei) provide Certificates of Analysis (CoA) documenting batch-specific purity data: assay (98.0–102.0%), particle size distribution, moisture, heavy metals, and functional tests (disintegration time in model tablets) 6,15. Traceability via batch numbers and compliance with cGMP (21 CFR Part 211) ensure consistent purity 6,15.
Purity directly influences critical quality attributes (CQAs) of drug products, including disintegration, dissolution, content uniformity, and stability:
High-purity Croscarmellose Sodium (≥98% assay) at 2–5% w/w in tablets achieves disintegration times <60 seconds and >85% API dissolution within 15 minutes 7,12. In ibandronate sodium tablets, 10–15% high-purity Croscarmellose Sodium (D50 = 100 μm) combined with microcrystalline cellulose (D50 = 80–110 μm) yields >60% dissolution at 5 minutes and >85% at 15 minutes, meeting bioequivalence requirements 7. Impurities (e.g., soluble carboxymethylcellulose) reduce wicking efficiency, delaying disintegration to >5 minutes 3,7.
For entacapone and nitecapone formulations, 8–16% high-purity Croscarmellose Sodium significantly enhances release rates compared to 0.5–5% conventional disintegrants, with 10–14% being optimal for balancing rapid disintegration and tablet hardness (17–21 SCU) 5,12. Purity-related particle size uniformity ensures reproducible disintegration across batches 5,12.
In taste-masking applications, Croscarmellose Sodium purity is critical for coating bitter APIs (e.g., dextromethorphan, pseudoephedrine) 1,4. High-purity grades (15–28% w/w coating, preferably 18–25%) applied via fluidized-bed coating to API particles (50–500 μm, <1% fines <60 μm) achieve effective taste masking while preserving rapid tablet disintegration (<60 seconds) 1,4. Impurities or excessive fines (<60 μm) compromise coating integrity, allowing API dissolution in saliva and bitter taste perception 4. Binders (e.g., hydroxypropylmethylcellulose, 2–5% w/w) enhance coating adhesion without affecting purity-dependent performance 4.
High-purity Croscarmellose Sodium improves API distribution in low-dose formulations (e.g., linagliptin 5 mg tablets) 8. At 10–20% w/w, it prevents API agglomeration and ensures content uniformity (RSD <2%) without milling, as demonstrated in formulations meeting USP <905> acceptance criteria 8. Impurities (e.g., moisture >10%) cause premature hydration and poor flowability, increasing segregation risk and content uniformity failures 8.
High-purity Croscarmellose Sodium minimizes API degradation in stress stability studies. Benzimidazole derivative tablets with 3–20% high-purity Croscarmellose Sodium show <0.02% total impurity increase after 7 days at 50°C/90% RH, compared to >0.5% with lower-purity grades 3. Similarly, 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid formulations (1:1 to 1:15 API:Croscarmellose Sodium ratio) exhibit no impurity formation over 6 months at 40°C/75% RH when using pharmaceutical-grade material 6,15. Impurities (e.g., residual acids, metals) catalyze hydrolysis or oxidation, particularly for moisture-sensitive APIs 3,6,15.
High-purity Croscarmellose Sodium is the gold standard superdisintegrant for immediate-release tablets, used at 2–5% w/w in direct compression and 3–8% w/w in wet granulation 5,7,12. In orally disintegrating tablets (ODTs), 5–25% w/w (preferably 8–13%) combined with sweeteners (e.g., mannitol, aspartame) achieves <60-second disintegration and acceptable palatability 14. For sustained-release formulations, 3–20% w/w Croscarmellose Sodium with hydrophobic bases (e.g., glyceryl behenate) or water-soluble polymers (e.g., hydroxypropylmethylcellulose) modulates drug release over 8–12 hours while maintaining tablet integrity under gastrointestinal peristalsis 9,13.
Case Study: Ibandronate Sodium Tablets — Osteoporosis Therapy
High-purity Croscarmellose Sodium (11–15% w/w, D50 = 100 μm) in direct-compression tablets (150 mg ibandronate sodium) achieves >60% dissolution at 5 minutes, ensuring rapid gastric absorption and minimizing esophageal irritation 7. Purity-driven particle size control (80–110 μm microcrystalline cellulose) prevents content uniformity issues in high-dose formulations 7.
In body powders, 2–20% w/w (preferably 5–20%) high-purity Croscarmellose Sodium enhances moisture absorption (≥20% w/w water uptake) without forming pastes, maintaining acceptable skin feel when combined with talc or starch (80–98% w/w) 2. Purity ensures fibrous structure integrity upon hydration, preventing cosmetic unacceptability (gumminess) observed with <98% purity grades 2. Applications include antiperspirants, baby powders, and wound dressings requiring high absorbency and non-irritating profiles 2.
Implement multi-tier testing protocols:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| FMC CORPORATION | Taste-masked pharmaceutical tablets for bitter-tasting active agents such as dextromethorphan and pseudoephedrine, particularly in pediatric chewable formulations requiring palatability and rapid disintegration. | Ac-Di-Sol | High-purity croscarmellose sodium (15-28% w/w coating) achieves effective taste masking of bitter APIs while preserving rapid tablet disintegration (<60 seconds). Particle size control (50-500 μm, <1% fines <60 μm) ensures coating integrity and prevents API dissolution in saliva. |
| ORION CORPORATION | Immediate-release oral tablets for catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease therapy, requiring rapid dissolution and enhanced bioavailability of poorly soluble active ingredients. | Entacapone/Nitecapone Tablets | High-purity croscarmellose sodium at 8-16% w/w (optimally 10-14%) significantly enhances drug release rates compared to conventional 0.5-5% disintegrants, achieving >85% dissolution within 15 minutes while maintaining tablet hardness of 17-21 SCU. |
| LABORATORIOS LICONSA S.A. | Direct-compression osteoporosis therapy tablets (150 mg ibandronate sodium) requiring rapid gastric absorption, minimized esophageal irritation, and consistent content uniformity in high-dose formulations. | Ibandronate Sodium Tablets | Pharmaceutical-grade croscarmellose sodium (11-15% w/w, D50=100 μm) combined with microcrystalline cellulose (D50=80-110 μm) achieves >60% dissolution at 5 minutes and >85% at 15 minutes, meeting bioequivalence requirements with minimal content uniformity variation (RSD <2%). |
| SANOVEL ILAC SANAYI VE TICARET A.S. | Low-dose DPP-4 inhibitor tablets for type 2 diabetes management, requiring precise content uniformity, chemical stability with primary amine-containing APIs, and compatibility with moisture-sensitive active ingredients. | Linagliptin Formulations | High-purity croscarmellose sodium (10-20% w/w) ensures content uniformity (RSD <2%) in low-dose formulations (5 mg) without milling, preventing API agglomeration and meeting USP <905> acceptance criteria while minimizing degradation products (<0.02% impurity increase under stress conditions). |
| AMERICAN HOME PRODUCTS CORPORATION | Calcium supplement compressed tablets for bone deficiency treatment, requiring long-term storage stability, consistent disintegration performance under stress conditions, and acceptable swallowing characteristics for patient compliance. | TRI-TAB Calcium Supplement | High-purity croscarmellose sodium (0.5-1.5% w/w) with sodium lauryl sulfate (50-100% of croscarmellose weight) prevents disintegration time aging in tricalcium phosphate tablets (≥80% w/w), maintaining <5 minutes disintegration after 2 weeks storage at 40°C/75% RH versus >30 minutes without optimization. |